Abstract

The human integrin VLA (very late activation antigens)-4 (CD49d/CD29), the leukocyte receptor for both the CS-1 region of plasma fibronectin (Fn) and the vascular cell surface adhesion molecule-1 (VCAM-1), also mediates homotypic aggregation upon triggering with specific anti-VLA-4 monoclonal antibody (mAb). Epitope mapping of this integrin on the human B-cell line Ramos, performed with a wide panel of anti-VLA-4 mAb by both cross-competitive cell binding and protease sensitivity assays, revealed the existence of three topographically distinct epitopes on the alpha 4 chain, referred to as epitopes A-C. By testing this panel of anti-VLA-4 mAb for inhibition of cell binding to both a 38-kDa Fn fragment containing CS-1 and to VCAM-1, as well as for induction and inhibition of VLA-4 mediated homotypic cell adhesion, we have found overlapping but different functional properties associated with each epitope. Anti-alpha 4 mAb recognizing epitope B inhibited cell attachment to both Fn and VCAM-1, whereas mAb against epitope A did not block VCAM-1 binding and only partially inhibited binding to Fn. In contrast, mAb directed to epitope C did not affect cell adhesion to either of the two VLA-4 ligands. All mAb directed to site A, as well as a subgroup of mAb recognizing epitope B (called B2), were able to induce cell aggregation, but this effect was not exerted by mAb specific to site C and by a subgroup against epitope B (called B1). Moreover, although anti-epitope C and anti-epitope B1 mAb did not trigger aggregation, those mAb blocked aggregation induced by anti-epitope A or B2 mAb. In addition, anti-epitope A mAb blocked B2-induced aggregation, and conversely, anti-epitope B2 mAb blocked A-induced aggregation. Further evidence for multiple VLA-4 functions is that anti-Fn and anti-VCAM-1 antibodies inhibited binding to Fn or to VCAM-1, respectively, but did not affect VLA-4-mediated aggregation. In summary, we have demonstrated that there are at least three different VLA-4-mediated adhesion functions, we have defined three distinct VLA-4 epitopes, and we have correlated these epitopes with the different functions of VLA-4.

Highlights

  • From the SSeccion de Inmunologin, Hospital dlea Princesa, Universidad Autonoma de Madrid and the **Centro de Investigaciones Biologicas, 28006 Madrid, Spain, the VDiuision of Tumor Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, and 11Biogen, Inc., Cambridge, Massachusetts 02142

  • A wide panel of unlabeled monoclonal antibody (mAb) was tested for the ability to inhibit binding by eight different lZ5I-labeledantiVLA-4 mAb(i.e.HP1/1, HP1/2, HP1/7, HP2/1, HP2/4, L25, B-5G10, and B-5E2) to theB- lymphoblastoid cell line Ramos (Table I).On the basis of this inhibition,all anti-very late activation antigens (VLA)-4 mAb clustered into three distinctclasses: group 1mAb inhibited binding of labeled HP1/1 andHP1/7; group 2 mAb blocked attachment of HP1/2, HP2/1, HP2/4, and L25; and group 3 mAb inhibited binding of B-5G10 and B-5E2 (Table I)

  • Ramos cells were incubated with increasing concentrations of Pronase, and mAb reactivity was measured by flow cytometry

Read more

Summary

Introduction

From the SSeccion de Inmunologin, Hospital dlea Princesa, Universidad Autonoma de Madrid and the **Centro de Investigaciones Biologicas, 28006 Madrid, Spain, the VDiuision of Tumor Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, and 11Biogen, Inc., Cambridge, Massachusetts 02142. The CS-1 region of plasma fibronectin (Fn) and the vascular cell surface adhesion molecule- 1 (VCAM-l), mediates homotypic aggregation upon triggering with specific anti-VLA-4 monoclonal antibody (mAb).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call